From api.bing.com
()
Acomplia (Rimonabant) from Sanofi-Aventis was taken off from the European market in 2008 following reports of psychiatric disorders in patients. The ban on Acomplia led to more aggressive competition between Xenical and Reductil, the leading obesity drugs in 2009.
More perspectives...
Approaching Support- Sanofi-AventisTradersHuddle.comNew York, December 16th (TradersHuddle.com) - Shares of Sanofi-Aventis (NYSE:SNY) ended close to calculated support at $33.64 with current price action placing the stock near levels that will raise attention of traders looking for an entry point. ...and more »
More perspectives...
From news.google.com
()
Dr. Rob Koremans to succeed Dr. Gerard van Odijk as President and CEO of Teva ...MarketWatch (press release)Dr. Koremans joins Teva after serving as CEO for Zentiva and most recently Senior Vice President Generic Strategy and Development at Sanofi-Aventis. After six intensive years, Dr. Gerard van Odijk, Teva Europe's current President and CEO has decided to ...and more »
More perspectives...
From news.google.com
()
MedPage TodayFDA : Patients With Permanent AF Should Not Take Multaq®InjuryBoard.comThe drug, sold by Sanofi-Aventis, is designed to prevent potentially deadly arrhythmia and make the heart beat normally. The safety agency's latest advisory said that patients with a "permanent" version of the abnormal heartbeat called atrial ...Washington Week: Medicare Cut Averted in Nick of TimeMedPage Todayall 2 news articles »
More perspectives...
From news.google.com
()
Hope and Remembrance tree litMyCentralJersey.comDonations for the Hope and Remembrance Tree will be accepted at the sanofi-aventis US Wellness Boutique at The Steeplechase Cancer Center, 30 Rehill Ave. in Somerville. Donations may also be made online at ...and more »
More perspectives...
From news.google.com
()
Sanofi-Aventis to launch reusable insulin pens in IndiaNDTVFrench drugmaker Sanofi-Aventis plans to launch reusable insulin pens in India in the second quarter of 2011. Sanofi-Aventis will also launch combiflam cream in the Indian market in January 2011 French drugmaker Sanofi-Aventis plans to launch reusable ...
More perspectives...
From news.google.com
()
Sanofi-Aventis to take longer on Shan5 relaunchBusiness StandardFrench vaccine major Sanofi-Aventis is expected to relaunch the pentavalent Shan5 vaccine produced by its Indian subsidiary, Shantha Biotech, only in 2013. It does not want to take further chances after the World Health Organisation (WHO) removed the ...
More perspectives...
From news.google.com
()
Overview
Rimonabant was not approved by the FDA due to concerns about suicidal tendencies in patients. Sanofi-Aventis had hoped to release Rimonabant as a weight loss drug.
Sorted by: Top Rated
By
tyronlenzming
on
From:
www.gobladder.info
By
tyronlenzming
on
From:
www.gobladder.info
By
guomi77
on
From:
www.goallergies.info
